Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cancer

A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker — the quantity of tumor-infiltrating lymphocytes in a biopsy — appears irrelevant when trastuzumab is used. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *